David Coughlin1,2,3,4, Sharon X Xie5,6, Mendy Liang1,2, Andrew Williams1,2, Claire Peterson1,2, Daniel Weintraub1,4,7, Corey T McMillan1,3, David A Wolk1,5, Rizwan S Akhtar1,4, Howard I Hurtig1,4, H Branch Coslett1,8, Roy H Hamilton1,8, Andrew D Siderowf1,4, John E Duda1,7, Katya Rascovsky1,3, Edward B Lee9,10,5, Virginia M-Y Lee9,10,5, Murray Grossman1,3, John Q Trojanowski9,10,5, David J Irwin1,2,3. 1. Department of Neurology, Perelman School of Medicine at the University of Pennsylvania. 2. Digital Neuropathology Laboratory, Perelman School of Medicine at the University of Pennsylvania. 3. Frontotemporal Dementia Center, Perelman School of Medicine at the University of Pennsylvania. 4. Parkinson's Disease and Movement Disorders Center, Perelman School of Medicine at the University of Pennsylvania. 5. Alzheimer's Disease Center, Perelman School of Medicine at the University of Pennsylvania. 6. Department of Biostatistics, Epidemiology and Informatics Perelman School of Medicine at the University of Pennsylvania. 7. Michael J. Crescenz VA Medical Center, Parkinson's Disease Research, Education, and Clinical Center, Philadelphia, PA, USA 19104. 8. Center for Cognitive Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. 9. Department of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania. 10. Center for Neurodegenerative Disease Research, Perelman School of Medicine at the University of Pennsylvania.
Abstract
OBJECTIVE: To use digital histology in a large autopsy cohort of Lewy body disorder (LBD) patients with dementia to test the hypotheses that co-occurring Alzheimer disease (AD) pathology impacts the anatomic distribution of α-synuclein (SYN) pathology and that co-occurring neocortical tau pathology in LBDs associates with worse cognitive performance and occurs in a pattern differing from AD. METHODS: Fifty-five autopsy-confirmed LBD (Parkinson disease with dementia, n = 36; dementia with Lewy bodies, n = 19) patients and 25 AD patients were studied. LBD patients were categorized as having moderate/severe AD copathology (SYN + AD = 20) or little/no AD copathology (SYN-AD = 35). Digital measures of tau, β-amyloid (Aβ), and SYN histopathology in neocortical and subcortical/limbic regions were compared between groups and related to antemortem cognitive testing. RESULTS: SYN burden was higher in SYN + AD than SYN-AD in each neocortical region (F1, 54 = 5.6-6.0, p < 0.02) but was equivalent in entorhinal cortex and putamen (F1, 43-49 = 0.7-1.7, p > 0.2). SYN + AD performed worse than SYN-AD on a temporal lobe-mediated naming task (t27 = 2.1, p = 0.04). Antemortem cognitive test scores inversely correlated with tau burden (r = -0.39 to -0.68, p < 0.05). AD had higher tau than SYN + AD in all regions (F1, 43 = 12.8-97.2, p < 0.001); however, SYN + AD had a greater proportion of tau in the temporal neocortex than AD (t41 = 2.0, p < 0.05), whereas AD had a greater proportion of tau in the frontal neocortex than SYN + AD (t41 = 3.3, p < 0.002). SYN + AD had similar severity and distribution of neocortical Aβ compared to AD (F1, 40-43 = 1.6-2.0, p > 0.1). INTERPRETATION: LBD patients with AD copathology harbor greater neocortical SYN pathology. Regional tau pathology relates to cognitive performance in LBD dementia, and its distribution may diverge from pure AD. Tau copathology contributes uniquely to the heterogeneity of cognitive impairment in LBD. Ann Neurol 2018; 1-13 ANN NEUROL 2019;85:259-271.
OBJECTIVE: To use digital histology in a large autopsy cohort of Lewy body disorder (LBD) patients with dementia to test the hypotheses that co-occurring Alzheimer disease (AD) pathology impacts the anatomic distribution of α-synuclein (SYN) pathology and that co-occurring neocortical tau pathology in LBDs associates with worse cognitive performance and occurs in a pattern differing from AD. METHODS: Fifty-five autopsy-confirmed LBD (Parkinson disease with dementia, n = 36; dementia with Lewy bodies, n = 19) patients and 25 ADpatients were studied. LBDpatients were categorized as having moderate/severe AD copathology (SYN + AD = 20) or little/no AD copathology (SYN-AD = 35). Digital measures of tau, β-amyloid (Aβ), and SYN histopathology in neocortical and subcortical/limbic regions were compared between groups and related to antemortem cognitive testing. RESULTS:SYN burden was higher in SYN + AD than SYN-AD in each neocortical region (F1, 54 = 5.6-6.0, p < 0.02) but was equivalent in entorhinal cortex and putamen (F1, 43-49 = 0.7-1.7, p > 0.2). SYN + AD performed worse than SYN-AD on a temporal lobe-mediated naming task (t27 = 2.1, p = 0.04). Antemortem cognitive test scores inversely correlated with tau burden (r = -0.39 to -0.68, p < 0.05). AD had higher tau than SYN + AD in all regions (F1, 43 = 12.8-97.2, p < 0.001); however, SYN + AD had a greater proportion of tau in the temporal neocortex than AD (t41 = 2.0, p < 0.05), whereas AD had a greater proportion of tau in the frontal neocortex than SYN + AD (t41 = 3.3, p < 0.002). SYN + AD had similar severity and distribution of neocortical Aβ compared to AD (F1, 40-43 = 1.6-2.0, p > 0.1). INTERPRETATION:LBDpatients with AD copathology harbor greater neocortical SYN pathology. Regional tau pathology relates to cognitive performance in LBD dementia, and its distribution may diverge from pure AD. Tau copathology contributes uniquely to the heterogeneity of cognitive impairment in LBD. Ann Neurol 2018; 1-13 ANN NEUROL 2019;85:259-271.
Authors: H I Hurtig; J Q Trojanowski; J Galvin; D Ewbank; M L Schmidt; V M Lee; C M Clark; G Glosser; M B Stern; S M Gollomp; S E Arnold Journal: Neurology Date: 2000-05-23 Impact factor: 9.910
Authors: Oscar L Lopez; James T Becker; Daniel I Kaufer; Ronald L Hamilton; Robert A Sweet; William Klunk; Steven T DeKosky Journal: Arch Neurol Date: 2002-01
Authors: Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman Journal: Acta Neuropathol Date: 2011-11-20 Impact factor: 17.088
Authors: G Stennis Watson; Brenna A Cholerton; Rachel G Gross; Daniel Weintraub; Cyrus P Zabetian; John Q Trojanowski; Thomas J Montine; Andrew Siderowf; James B Leverenz Journal: Alzheimers Dement Date: 2012-11-16 Impact factor: 21.566
Authors: Jennifer G Goldman; Caroline Williams-Gray; Roger A Barker; John E Duda; James E Galvin Journal: Mov Disord Date: 2014-04-15 Impact factor: 10.338
Authors: David J Irwin; Murray Grossman; Daniel Weintraub; Howard I Hurtig; John E Duda; Sharon X Xie; Edward B Lee; Vivianna M Van Deerlin; Oscar L Lopez; Julia K Kofler; Peter T Nelson; Gregory A Jicha; Randy Woltjer; Joseph F Quinn; Jeffery Kaye; James B Leverenz; Debby Tsuang; Katelan Longfellow; Dora Yearout; Walter Kukull; C Dirk Keene; Thomas J Montine; Cyrus P Zabetian; John Q Trojanowski Journal: Lancet Neurol Date: 2017-01 Impact factor: 44.182
Authors: Benoit I Giasson; Mark S Forman; Makoto Higuchi; Lawrence I Golbe; Charles L Graves; Paul T Kotzbauer; John Q Trojanowski; Virginia M-Y Lee Journal: Science Date: 2003-04-25 Impact factor: 47.728
Authors: Thomas J Montine; Sarah E Monsell; Thomas G Beach; Eileen H Bigio; Yunqi Bu; Nigel J Cairns; Matthew Frosch; Jonathan Henriksen; Julia Kofler; Walter A Kukull; Edward B Lee; Peter T Nelson; Aimee M Schantz; Julie A Schneider; Joshua A Sonnen; John Q Trojanowski; Harry V Vinters; Xiao-Hua Zhou; Bradley T Hyman Journal: Alzheimers Dement Date: 2015-08-29 Impact factor: 21.566
Authors: Bradley F Boeve; Dennis W Dickson; John E Duda; Tanis J Ferman; Douglas R Galasko; James E Galvin; Jennifer G Goldman; John H Growdon; Howard I Hurtig; Daniel I Kaufer; Kejal Kantarci; James B Leverenz; Carol F Lippa; Oscar L Lopez; Ian G McKeith; Andrew B Singleton; Angela Taylor; Debby Tsuang; Daniel Weintraub; Cyrus P Zabetian Journal: Mov Disord Date: 2016-08-05 Impact factor: 10.338
Authors: David G Coughlin; Helen Petrovitch; Lon R White; Joseph Noorigian; Kamal H Masaki; G Webster Ross; John E Duda Journal: Parkinsonism Relat Disord Date: 2019-03-28 Impact factor: 4.891
Authors: Cathrine Petersen; Amber L Nolan; Elisa de Paula França Resende; Zachary Miller; Alexander J Ehrenberg; Maria Luisa Gorno-Tempini; Howard J Rosen; Joel H Kramer; Salvatore Spina; Gil D Rabinovici; Bruce L Miller; William W Seeley; Helmut Heinsen; Lea Tenenholz Grinberg Journal: Acta Neuropathol Date: 2019-06-27 Impact factor: 17.088
Authors: Erica Howard; David J Irwin; Katya Rascovsky; Naomi Nevler; Sanjana Shellikeri; Thomas F Tropea; Meredith Spindler; Andres Deik; Alice Chen-Plotkin; Andrew Siderowf; Nabila Dahodwala; Daniel Weintraub; Leslie M Shaw; John Q Trojanowski; Sanjeev N Vaishnavi; David A Wolk; Dawn Mechanic-Hamilton; James F Morley; John E Duda; Murray Grossman; Katheryn A Q Cousins Journal: Neurology Date: 2021-02-16 Impact factor: 9.910
Authors: D G Coughlin; R Ittyerah; C Peterson; J S Phillips; S Miller; K Rascovsky; D Weintraub; A D Siderowf; J E Duda; H I Hurtig; D A Wolk; C T McMillan; P A Yushkevich; M Grossman; E B Lee; J Q Trojanowski; D J Irwin Journal: Neuropathol Appl Neurobiol Date: 2020-09-24 Impact factor: 8.090
Authors: Tanis J Ferman; Naoya Aoki; Bradley F Boeve; Jeremiah A Aakre; Kejal Kantarci; Jonathan Graff-Radford; Joseph E Parisi; Jay A Van Gerpen; Neill R Graff-Radford; Ryan J Uitti; Otto Pedraza; Melissa E Murray; Zbigniew K Wszolek; R Ross Reichard; Julie A Fields; Owen A Ross; David S Knopman; Ronald C Petersen; Dennis W Dickson Journal: Neurology Date: 2020-06-19 Impact factor: 9.910
Authors: David G Coughlin; Jeffrey S Phillips; Emily Roll; Claire Peterson; Rebecca Lobrovich; Katya Rascovsky; Molly Ungrady; David A Wolk; Sandhitsu Das; Daniel Weintraub; Edward B Lee; John Q Trojanowski; Leslie M Shaw; Sanjeev Vaishnavi; Andrew Siderowf; Ilya M Nasrallah; David J Irwin; Corey T McMillan Journal: Neurobiol Aging Date: 2020-08-21 Impact factor: 4.673